Synthesis and evaluation of novel dual GSK-3β/HDAC inhibitor as an anti-Alzheimer agent
Implementing Organization
National Institute of Pharmaceutical Education and Research, Raebareli
Principal Investigator
Dr. Abha Sharma
Associate Professor
|
National Institute of Pharmaceutical Education and Research, Raebareli
About
A dual classical GSK-3β/epigenetic HDAC6 inhibitor is designed using a multi-target strategy for modulating Alzheimer's disease (AD) targets. The pyrimidone-based series of derivatives will be synthesized using four multistep schemes. The proposed molecules will undergo enzymatic assays, toxicity studies, acute toxicity, memory and cognitive improvement evaluation, and biochemical evaluation. Only one international research study is available.
Science and Engineering Research Board (SERB), New Delhi
Quick Information
Area of Research
Life Sciences & Biotechnology
Focus Area
Pharmaceuticals, Neurology
Start Year
2023
End Year
2025
Sanction Amount
₹ 37.31 L
Status
Completed
Contact
abha.sharma@niperraebareli.edu.in
Output
No. of Research Paper
00
Technologies (If Any)
00
No. of PhD Produced
00
No. of Patents
Filed :00
Grant :00
Disclaimer:
Information available on this portal is sourced from various organizations and is provided for informational purposes only. Users are advised to verify details from the respective official sources.
Please enter your details
Please provide your name and email to continue. Your details are saved in this browser for future use.
Latest Updates
Loading…
⚠️
You are leaving this website
You are about to be redirected to an external website that is not operated by
India Science, Technology & Innovation (ISTI) Portal.